<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004038</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02273</org_study_id>
    <secondary_id>FCCC-97009</secondary_id>
    <secondary_id>NCI-T97-0042</secondary_id>
    <secondary_id>CDR0000066480</secondary_id>
    <nct_id>NCT00004038</nct_id>
  </id_info>
  <brief_title>Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer</brief_title>
  <official_title>Pilot Study of p53 Intralesional Gene Therapy With Chemotherapy in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of gene therapy plus chemotherapy in treating&#xD;
      patients who have breast cancer. Inserting the p53 gene into a person's cancer cells may&#xD;
      improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.&#xD;
      Combining chemotherapy with gene therapy may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the effect of adenovirus p53 (Ad-p53) on chemotherapy-induced apoptosis in&#xD;
      lesions in patients with breast cancer.&#xD;
&#xD;
      II. Determine p53 protein expression following intralesional injections of Ad-p53 by&#xD;
      immunohistochemistry and reverse transcriptase polymerase chain reaction in this patient&#xD;
      population.&#xD;
&#xD;
      III. Determine the time course and magnitude of the development of a humoral antibody&#xD;
      response to the adenoviral vector in this patient population.&#xD;
&#xD;
      IV. Determine the ability of transfected p53 to upregulate downstream signals important in G1&#xD;
      arrest by assaying for WAF1 mRNA and apoptosis in this patient population.&#xD;
&#xD;
      V. Determine the toxicities and side effects of intralesional injections of Ad-p53 given in&#xD;
      combination with standard chemotherapy in patients with cutaneous and subcutaneous metastatic&#xD;
      breast cancer amenable to injections and biopsies.&#xD;
&#xD;
      VI. Determine if there is an increase in apoptosis induced by Ad-53 compared to baseline in&#xD;
      this patient population.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo biopsy of one of their skin nodules prior to any treatment. Patients receive&#xD;
      the Ad-p53 gene therapy in one nodule and injection of a second nodule with Dulbecco's&#xD;
      phosphate buffered saline. The next day, patients begin chemotherapy, which may be given&#xD;
      weekly and continues every 21-28 days for up to 6 courses. On day 3, patients return for&#xD;
      biopsy of injected nodules. Biopsies are only performed during the first course. Patients may&#xD;
      receive further injections of the Ad-p53 gene with subsequent courses of chemotherapy, for up&#xD;
      to six courses.&#xD;
&#xD;
      Patients are followed monthly for 4 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <primary_completion_date type="Actual">May 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo biopsy of one of their skin nodules prior to any treatment. Patients receive the Ad-p53 gene therapy in one nodule and injection of a second nodule with Dulbecco's phosphate buffered saline. The next day, patients begin chemotherapy, which may be given weekly and continues every 21-28 days for up to 6 courses. On day 3, patients return for biopsy of injected nodules. Biopsies are only performed during the first course. Patients may receive further injections of the Ad-p53 gene with subsequent courses of chemotherapy, for up to six courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5CMV-p53 gene</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed epithelial breast cancer&#xD;
&#xD;
          -  At least 3 cutaneous or subcutaneous lesions required&#xD;
&#xD;
          -  Measurable disease that includes, but is not limited to, cutaneous or subcutaneous&#xD;
             metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: Over 18&#xD;
&#xD;
          -  Performance status: ECOG 0-2&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm3&#xD;
&#xD;
          -  Hemoglobin greater than 8 g/dL&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
          -  Bilirubin less than 2 mg/dL&#xD;
&#xD;
          -  PT/PTT within normal range&#xD;
&#xD;
          -  SGOT/SGPT less than 2 times upper limit of normal&#xD;
&#xD;
          -  Creatinine less than 1.8 mg/dL&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Concurrent cytotoxic chemotherapy allowed, if stable and responding&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy, if starting a new regimen&#xD;
&#xD;
          -  At least 4 weeks since radiotherapy&#xD;
&#xD;
          -  Prior adjuvant radiotherapy to the chest wall allowed&#xD;
&#xD;
          -  At least 6 months since radiotherapy to lesions that are to be injected&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret von Mehren, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2001</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>May 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2004</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

